Researchers at the Department of Urology, University of Michigan, Ann Arbor, Michigan evaluated the complications associated with the male bone-anchored sling (BAS) to determine the appropriate preoperative counseling for men considering surgery. The BAS is a surgical option for the treatment of stress urinary incontinence (SUI) due to intrinsic sphincter deficiency. The researchers reviewed 119 [...]
It was announced by the pharmaceutical manufacture, Amgen, that they are recalling certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) The recall is prompted because the vials may contain extremely thin glass flakes (lamellae) that are barely visible. The lamellae result from the interaction of the formulation with glass vials over the shelf life of [...]
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Researchers at the Cedars-Sinai Medical Center in Los Angeles set out to see if there are any health benefits to be derived from a massage, or is a massage just relaxing to your muscles? […]
All the drugs used as 2nd line hormone therapy are only partially effective. Only some individuals respond and receive any benefit from them, but there has been some recent research into combining the drugs. At the last American Society of Clinical Oncology (ASCO), Dr. Eric Small, M.D. presented a abstract about his recent experimentation of [...]
Somastatin is a naturally occurring hormone that affects the levels of other hormone production in the body. Its most common drug use today is to treat giantism and acromegaley, a disease characterized by an over abundance of growth hormones. There is laboratory evidence that somastatin analogs such as octreotide acetate (Sandostatin/Sandoz) can affect the growth [...]
Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]
One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]
At some point in the progression of advanced prostate cancer the usual initial standard of care, hormone therapy (ADT2 or ADT3), will fail to control the progression of the cancer. Commonly, when ADT does fail we will experience an increase in our PSA scores and often see signs of disease progression on imaging tests. For [...]
For men with advanced prostate cancer adjuvant radiation therapy improves the cancer-specific survival of men with seminal vesicle invasion, even in the presence of nodal metastases. This underscores the need for multi-modal treatment approaches in advanced prostate cancer patients. Joel T. Nowak, M.A., M.S.W.
